118 related articles for article (PubMed ID: 28901501)
1. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in vitro.
Engl T; Rutz J; Maxeiner S; Juengel E; Roos F; Khoder W; Bechstein WO; Nelson K; Tsaur I; Haferkamp A; Blaheta RA
Mol Med Rep; 2017 Nov; 16(5):7064-7071. PubMed ID: 28901501
[TBL] [Abstract][Full Text] [Related]
2. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
4. Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.
Tsaur I; Makarević J; Juengel E; Gasser M; Waaga-Gasser AM; Kurosch M; Reiter M; Wedel S; Bartsch G; Haferkamp A; Wiesner C; Blaheta RA
Br J Cancer; 2012 Aug; 107(5):847-55. PubMed ID: 22782340
[TBL] [Abstract][Full Text] [Related]
5. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.
Juengel E; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Tsaur I; Nelson K; Bechstein WO; Haferkamp A; Blaheta RA
Oncotarget; 2016 Dec; 7(51):85208-85219. PubMed ID: 27863441
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK.
Relja B; Meder F; Wang M; Blaheta R; Henrich D; Marzi I; Lehnert M
Int J Oncol; 2011 Mar; 38(3):879-85. PubMed ID: 21206971
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
11. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
12. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
13. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells.
Masumoto A; Arao S; Otsuki M
Hepatology; 1999 Jan; 29(1):68-74. PubMed ID: 9862852
[TBL] [Abstract][Full Text] [Related]
14. alpha6beta1 integrin expression in hepatocarcinoma cells: regulation and role in cell adhesion and migration.
Nejjari M; Hafdi Z; Dumortier J; Bringuier AF; Feldmann G; Scoazec JY
Int J Cancer; 1999 Nov; 83(4):518-25. PubMed ID: 10508489
[TBL] [Abstract][Full Text] [Related]
15. [Integrin alpha3beta1 mediates hepatocellular carcinoma cell adhesion and chemotaxis to type IV collagen].
Fu BH; Wu ZZ; Qin J; Li P; Liu LP; Cai SX; Dong C
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):967-71. PubMed ID: 12899798
[TBL] [Abstract][Full Text] [Related]
16. Expression of integrin beta1 and its roles on adhesion between different cell cycle hepatocellular carcinoma cells (SMMC-7721) and human umbilical vein endothelial cells.
Song G; Luo Q; Qin J; Wang B; Cai S
Colloids Surf B Biointerfaces; 2004 Apr; 34(4):247-52. PubMed ID: 15261064
[TBL] [Abstract][Full Text] [Related]
17. Laminin deposition to type IV collagen enhances haptotaxis, chemokinesis, and adhesion of hepatoma cells through beta1-integrins.
Torimura T; Ueno T; Kin M; Harad R; Nakamura T; Sakamoto M; Kumashiro R; Yano H; Kojiro M; Sata M
J Hepatol; 2001 Aug; 35(2):245-53. PubMed ID: 11580147
[TBL] [Abstract][Full Text] [Related]
18. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759798
[TBL] [Abstract][Full Text] [Related]
19. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
Navarro-Villarán E; Tinoco J; Jiménez G; Pereira S; Wang J; Aliseda S; Rodríguez-Hernández MA; González R; Marín-Gómez LM; Gómez-Bravo MA; Padillo FJ; Álamo-Martínez JM; Muntané J
PLoS One; 2016; 11(8):e0160979. PubMed ID: 27518575
[TBL] [Abstract][Full Text] [Related]
20. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
